Literature DB >> 17763528

A Bayesian predictive two-stage design for phase II clinical trials.

Valeria Sambucini1.   

Abstract

In this paper, we propose a Bayesian two-stage design for phase II clinical trials, which represents a predictive version of the single threshold design (STD) recently introduced by Tan and Machin. The STD two-stage sample sizes are determined specifying a minimum threshold for the posterior probability that the true response rate exceeds a pre-specified target value and assuming that the observed response rate is slightly higher than the target. Unlike the STD, we do not refer to a fixed experimental outcome, but take into account the uncertainty about future data. In both stages, the design aims to control the probability of getting a large posterior probability that the true response rate exceeds the target value. Such a probability is expressed in terms of prior predictive distributions of the data. The performance of the design is based on the distinction between analysis and design priors, recently introduced in the literature. The properties of the method are studied when all the design parameters vary.

Mesh:

Year:  2008        PMID: 17763528     DOI: 10.1002/sim.3021

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

Review 2.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

3.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

4.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

5.  The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee
Journal:  Pharm Stat       Date:  2021-05-19       Impact factor: 1.234

6.  Comparing Bayesian early stopping boundaries for phase II clinical trials.

Authors:  Liyun Jiang; Fangrong Yan; Peter F Thall; Xuelin Huang
Journal:  Pharm Stat       Date:  2020-07-27       Impact factor: 1.234

7.  Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.

Authors:  Eriko Sumi; Tomoharu Sugie; Kenichi Yoshimura; Harue Tada; Takafumi Ikeda; Eiji Suzuki; Yoshimasa Tanaka; Satoshi Teramukai; Akira Shimizu; Masakazu Toi; Nagahiro Minato
Journal:  J Transl Med       Date:  2014-11-25       Impact factor: 5.531

8.  Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.

Authors:  Dung-Tsa Chen; Michael J Schell; William J Fulp; Fredrik Pettersson; Sungjune Kim; Jhanelle E Gray; Eric B Haura
Journal:  Transl Cancer Res       Date:  2019-07       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.